![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Low Rates of Integrase Resistance for Elvitegravir and Raltegravir through Week 96 in the Phase 3 Clinical Study GS-US-183-0145
|
|
|
Reported by Jules Levin
IAC July 22-27 2012 Wash DC
NA Margot, MS Rhee, J Szwarcberg, and MD Miller
Gilead Sciences, Inc., Foster City, CA, USA
![IAC1.gif](../images/072712/072712-4/IAC1.gif)
![IAC2.gif](../images/072712/072712-4/IAC2.gif)
![IAC3.gif](../images/072712/072712-4/IAC3.gif)
![IAC4.gif](../images/072712/072712-4/IAC4.gif)
![IAC5.gif](../images/072712/072712-4/IAC5.gif)
![IAC6.gif](../images/072712/072712-4/IAC6.gif)
![IAC7.gif](../images/072712/072712-4/IAC7.gif)
![IAC8.gif](../images/072712/072712-4/IAC8.gif)
![IAC9.gif](../images/072712/072712-4/IAC9.gif)
![IAC10.gif](../images/072712/072712-4/IAC10.gif)
![IAC11.gif](../images/072712/072712-4/IAC11.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|